Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
September 5, 2024
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal. These new regulations pose significant challenges for smaller biopharma companies like Halia. They risk driving innovation overseas due to higher costs and longer timelines. Halia remains, however, committed to identifying the most effective, lowest doses in early trials to deliver safe and potent treatments to patients.
Recent News
- Freyya Closes Oversubscribed Pre-Seed Financing to Advance FDA Regulatory Milestones, Commercialization
- In Memory of Dr. Michael Rinck, Founder, MT Promedt Consulting GmbH
- bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
- Priority Review Granted for PolarityBio’s SkinTE for Treatment of Diabetic Foot Ulcers
- National Institutes of Health Award Inherent Biosciences a Direct-to-Phase II SBIR Grant
- Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
